MEI Pharma reports Phase I trial data for drug candidate for refractory tumors MEI Pharma announced data from the ongoing Phase I clinical trial of its mitochondrial inhibitor drug candidate ME-344 in patients with refractory solid tumors. Eight of the 23 patients achieved disease control, including one confirmed partial response in a patient with refractory small cell lung cancer - duration 52+ weeks - and seven patients with prolonged stable disease ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg/kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg.
News For MEIP From The Last 14 Days
Check below for free stories on MEIP the last two weeks.